A plain-language summary of recent research on predicting survival and improving care
What is Pseudomyxoma Peritonei (PMP)?
Pseudomyxoma peritonei (PMP) is a rare cancer that starts in the appendix and spreads a mucus-like substance inside the belly (the peritoneal cavity). In its high-grade form, it’s more aggressive. A particularly serious subtype is called high-grade PMP with signet-ring cells, and this study focuses on both.
Why This Research Matters
Doctors have long known that two main factors predict how well a patient with high-grade PMP will do:
- How much cancer was found (the Peritoneal Cancer Index, or PCI)
- How completely surgery removed it (Completeness of Cytoreduction, or CCR)
But even when two patients have similar tumors and undergo the same surgery, their outcomes can look very different. Why? This 10-year study from a specialized center in China found a compelling answer: your body’s nutritional and inflammatory state matters too and it can be measured with a simple blood test before surgery. The link to the study is at the end of this post.
The Study at a Glance
- 223 patients with confirmed high-grade appendix PMP
- Treated between 2015 and 2024
Median survival in this group: 21 months (though this varied widely, many patients did better)
The Key Discovery: A Score That Predicts Survival
Researchers tested many blood-test markers. The one that added the most predictive value was called the Advanced Lung Cancer Inflammation Index (ALI) — despite the name, it turns out to be highly useful in appendix cancer too.
What is the ALI?
It combines three things your doctor can easily measure:
ALI = BMI × Albumin level ÷ Neutrophil-to-Lymphocyte Ratio
In plain English:
- BMI reflects your body mass and reserves
- Albumin is a blood protein reflecting nutritional health — low albumin suggests your body is stressed or malnourished
- Neutrophil-to-Lymphocyte Ratio (NLR) reflects inflammation — a high ratio means your immune system is in an overactivated, inflammatory state
A high ALI = better nourished + healthier immune balance = significantly better survival in this study.
A low ALI = nutritional depletion + high inflammation = linked to worse outcomes.
What Predicted Better or Worse Survival?
Associated with worse survival:
- Leaving visible cancer behind after surgery (incomplete removal)
- Signet-ring cell subtype (most aggressive form)
- High Ki-67 (cancer cells dividing rapidly)
- Elevated blood tumor markers CA19-9 and CA125
- Low ALI score
Associated with better survival:
- Complete or near-complete removal of all visible cancer
- Receiving HIPEC (heated chemotherapy into the abdomen during surgery)
- High ALI score
A New Prediction Tool: The Nomogram
The researchers built a nomogram — a scoring chart that helps doctors estimate a patient’s chances of surviving 1, 2, or 3 years after surgery. It combines eight factors:
- Pathological grade (standard high-grade vs. signet-ring cell type)
- Ki-67 (how fast cancer cells are growing)
- Completeness of cancer removal (CCR)
- Tumor spread score (PCI)
- CA125 blood level
- CA19-9 blood level
- Whether HIPEC was given
- ALI score ← the new addition
The tool was more than 80% accurate at predicting 1- and 2-year survival. It won’t tell any individual exactly what will happen, but it helps doctors identify who may need extra support and plan accordingly.
What This Could Mean for Your Care
The most hopeful practical implication: if a low ALI is identified before surgery, something can potentially be done about it.
If your ALI is low going into surgery, your team might:
- Refer you to a dietitian to boost protein intake and correct nutritional deficiencies
- Recommend prehabilitation — structured nutrition and exercise support to build your strength before the operation
- Discuss whether to delay surgery briefly to allow optimization
If your ALI is high going into surgery:
- You may be a strong candidate for proceeding directly to the major CRS + HIPEC procedure
- Your care team can feel more confident about your resilience
Important Limitations to Know
- This was a single center study in China — results need to be confirmed at other hospitals worldwide
- It was retrospective (looking back at past patients), not a controlled trial
- Data on some treatments like systemic chemotherapy and immunotherapy weren’t available
- The ALI cutoff used may differ at other centers
This is not yet standard practice everywhere, but it adds important evidence that nutrition and inflammation are meaningful, and potentially modifiable, factors in PMP outcomes.
Questions to Ask Your Doctor
- “Can you check my albumin level and neutrophil-to-lymphocyte ratio before surgery?”
- “Should I see a dietitian to optimize my nutrition beforehand?”
- “Will I receive HIPEC? If not, why not?”
- “Is this center experienced in high-volume CRS + HIPEC for PMP?”
- “Is my cancer standard high-grade, or high-grade with signet-ring cells?”
- “What do my CA19-9 and CA125 levels suggest about my prognosis?”
The Bottom Line
High-grade appendix PMP is a serious and rare diagnosis. But research like this is steadily building a more complete picture of what drives outcomes — and crucially, some of those factors may be improvable. The discovery that a simple, inexpensive blood score (the ALI) reflects survival adds a new tool for doctors and a new opportunity for patients: being well-nourished and managing inflammation before surgery may genuinely matter.
You are not just your tumor. Your body’s overall health, nutrition, and immune balance are part of your story — and they may be something you and your care team can actively work on together.
This post summarizes the preprint: “Advanced Lung Cancer Inflammation Index as a Prognostic Inflammation–Nutrition Marker in Appendiceal High-Grade Pseudomyxoma Peritonei: A 10-Year Single-Center Study” by Gao et al. (Research Square, 2026). This paper has not yet completed peer review. This post is for informational purposes only and is not medical advice — please discuss your individual situation with your care team.
Leave a Reply